Fennec Pharmaceuticals Inc. expected to post earnings of 1 cent a share - Earnings Preview

Fennec Pharmaceuticals

07/08/2026 16:39

Fennec Pharmaceuticals Inc. FENC.OQ FENC.O is expected to  show a rise in quarterly revenue when it reports  results on August 11 for the period ending June 30 2026
The Research Triangle Park North Carolina-based  company is expected to report a 67.0% increase in revenue to $16.118 million from $9.65 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Fennec Pharmaceuticals Inc. is for earnings of 1 cent per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Fennec Pharmaceuticals Inc. is $16.00, about 47.6% above its last closing price of $10.84
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.01
-0.01
0.01
Beat
220
Dec. 31 2026
0.02
0.04
-0.10
Missed
-385.7
Sep. 30 2025
-0.02
-0.02
-0.02
Met
6.5​
Jun. 30 2025
-0.03
-0.04
-0.11
Missed
-205.6
​​Mar. 31 2025
-0.08
-0.09
-0.04
Beat
55
Dec. 31 2024
0.44
0.17
-0.06
Missed
-136.1​
Sep. 30 2024
-0.14
-0.09
-0.21
Missed
-133.3
Jun. 30 2024
-0.11
-0.03
-0.20
Missed
-552.1
This summary was machine generated August 7 at 15:39 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)